Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
New multiple sclerosis phenotypic classification.
Patient reported outcome measures in neurogenic bladder.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Oxidative modification of serum proteins in multiple sclerosis.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Novel therapies for memory cells in autoimmune diseases.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
The interplay between the intestinal microbiota and the brain.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
New approaches in the management of multiple sclerosis.
Santhera to discontinue sale of Catena® in Canada
US court permits generic version of Teva MS drug a year sooner

Pages